SpaceX IPO is the biggest IPO in stock market history. Join the conversation.Click here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCalculus Vct Regulatory News (CLC)

Share Price Information for Calculus Vct (CLC)

Share Price is delayed by 15 minutes
Get Live Data
53.25    0.00 (0.00%)
Bid:
48.00
Ask:
58.50
Spread: 10.50 (21.875%)
Market Cap: £51.93m
CLC Live PriceLast checked at - London Stock Exchange

Intraday Calculus Vct Share Chart

Statement re Recommended Proposals for Merger

19 Jun 2017 07:00

RNS Number : 3923I
Neptune-Calculus Income &Growth VCT
19 June 2017
 

NEPTUNE-CALCULUS INCOME AND GROWTH VCT PLC - Recommended Proposals for Merger

19 June 2017

NEPTUNE-CALCULUS INCOME AND GROWTH VCT PLC ("The Company")

CALCULUS VCT PLC ("Calculus VCT")

 (Together the "Companies")

 

TIDM: NEP

 

RECOMMENDED PROPOSALS FOR A SPECIAL DIVIDEND OF 10.5p PER SHARE AND MERGER BETWEEN THE COMPANY AND CALCULUS VCT

 

SUMMARY

 

At the time of announcing the results for 2016, we stated that your Board was considering strategic options for the Company which might lead to proposals involving a significant return of capital to shareholders. Your Board is pleased to announce that it has agreed in principle with the board of Calculus VCT to merge the two VCTs on a relative net asset basis. Both Companies are managed by Calculus Capital Limited ("Calculus Capital").

 

Your board believes there will be significant benefits for all shareholders arising from the proposed merger with Calculus VCT which are set out below. The merger, which will follow the methodology used in the majority of VCT mergers, will be effected by means of placing the Company into members' voluntary liquidation pursuant to Section 110 of IA 1986 and the acquisition by Calculus VCT of all the Company's assets and liabilities in consideration for the issue of Shares in Calculus VCT, forming an enlarged VCT (the "Enlarged Company").

 

The Merger will be conditional upon certain conditions being satisfied which will be set out in the circulars to be posted in due course to the Companies' respective shareholders together with a prospectus in connection with the Merger (the "Prospectus").

 

Conditional upon the Merger being approved by shareholders, the Company intends to pay a special dividend of 10.5p per share to shareholders prior to completion of the Merger. This special dividend will be in addition to the 2 pence annual dividend declared at the time of publishing the 2016 results which is due for payment on 30 June 2017, subject to approval at the Company's upcoming Annual General Meeting.

 

In addition, conditional upon the Merger taking place, the Enlarged Company intends to seek further investment by way of an offer of new equity of up to £5 million to be allotted in the 2017/18 and 2018/19 tax years with an over-allotment option of up to a further £5 million (the "Offer").

 

If the Merger is effected, the Enlarged Company should have net assets in excess of £10 million, prior to any shares being issued in the Offer.

 

BENEFITS ANTICIPATED FROM THE MERGER

The Merger should result in the following benefits for Shareholders:

· a reduction in the expected annual running costs for Shareholders due to operational expenses being spread over a larger base;

· the opportunity for future buy backs, particularly for Shareholders who have held their shares for more than 5 years;

· a larger pool of distributable reserves to support future dividend payments; and

· exposure to a more diversified portfolio.

Additional attractive features of the Merger include:

· the Company's venture capital investment manager, Calculus Capital has agreed to contribute 33% of the costs of the Merger, meaning that the costs will be split evenly between Calculus Capital, the Company and Calculus VCT;

· no impact on the tax position of Shareholders, and

· existing VCT tax reliefs carry over and attach to the post-Merger shares for Shareholders and shareholders in Calculus VCT.

 

A reduction in the cost cap and expected annual running costs

 

Subject to the Merger taking place, Calculus Capital has agreed to increase its potential contribution to the running costs of the Enlarged Company by reducing the cost cap (excluding irrecoverable VAT, annual trail commission and performance incentive fees) to 3% of the net assets of the Enlarged Company at each financial year end. This compares to the current cost cap for Neptune shareholders of 3.5% of the net asset value of the Company at each financial year end.

THE ENLARGED COMPANY BOARD

It was announced on 25 April 2017 that Diane Seymour-Williams would be appointed as Non-Executive Chairman of the Company immediately following its AGM on 22 June 2017. It is proposed that, if the Merger is approved, Diane Seymour-Williams will join the Board of the Enlarged Company, which should then be:

· Michael O'Higgins;

· Arthur John Glencross;

· Kate Cornish-Bowden

· Steven Meeks; and

· Diane Seymour-Williams.

TIMETABLE

It was announced in Calculus VCT's Report and Accounts on 12 May 2017, that the merger of Calculus VCT's Ordinary, C and D Share classes was expected to take place on a date as soon as possible after 30 May 2017 when HMRC clearance for the share class merger is received. HMRC clearance is expected imminently and it is expected that that the Calculus VCT share class merger will take place as soon as possible thereafter.

Following the merger of the Calculus VCT share classes, it is expected that shareholder circulars seeking approval for the Merger and other related matters, together with the Prospectus, will be posted to the shareholders of the Company and Calculus VCT as soon as possible thereafter.

Subject to shareholders' approvals, it is expected that the Merger can be completed within 6 weeks of the date of posting.

Lesley Watkins

Company Secretary

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
STRQQLFFDQFLBBB
Date   Source Headline
22nd Apr 20263:39 pmRNSTransaction in Own Shares
31st Mar 20265:55 pmRNSDirectorate change
25th Mar 20262:23 pmRNSIssue of Equity
18th Feb 20263:14 pmRNSIssue of Equity
22nd Jan 20269:29 amRNSTransaction in Own Shares
16th Jan 20264:34 pmRNSNet Asset Value(s)
14th Jan 20263:00 pmRNSDividend Declaration
18th Dec 20252:30 pmRNSIssue of Equity
18th Dec 20252:30 pmRNSIssue of Equity
17th Dec 20253:15 pmRNSIssue of Equity
15th Dec 20253:10 pmRNSHalf-year Financial Report
14th Oct 20254:33 pmRNSTransaction in Own Shares
3rd Oct 202511:42 amRNSPublication of a Prospectus
2nd Oct 20254:29 pmRNSIssue of Equity
24th Sep 202511:22 amRNSResult of AGM & Change in Directorship
2nd Sep 20252:48 pmRNSIssue of Equity
28th Aug 202512:38 pmRNSPublication of Supplementary Prospectus
27th Aug 20252:52 pmRNSNet Asset Value
31st Jul 20259:46 amRNSAnnual Report with updated dividend details
30th Jul 202511:31 amRNSAnnual Financial Report &Related Party Transaction
3rd Jul 20259:17 amRNSIssue of Equity
10th Jun 20254:41 pmRNSTransaction in Own Shares
5th Jun 20254:39 pmRNSTransaction in Own Shares
4th Apr 20255:15 pmRNSIssue of Equity
26th Mar 20253:21 pmRNSIssue of Equity
11th Mar 20255:11 pmRNSChange of auditor
20th Feb 20254:30 pmRNSIssue of Equity
12th Feb 20254:39 pmRNSTransaction in Own Shares
21st Jan 20255:11 pmRNSNet Asset Value(s)
10th Jan 20253:46 pmRNSIssue of Equity update
18th Dec 20244:24 pmRNSIssue of Equity - 18 December 2024
5th Dec 20245:25 pmRNSHalf-year Report
14th Oct 20241:40 pmRNSPublication of a Prospectus
8th Oct 20245:23 pmRNSTransaction in Own Shares
9th Sep 202411:48 amRNSStatement re Intention to Fund Raise
29th Aug 20245:32 pmRNSIssue of Equity
22nd Aug 20244:27 pmRNSResults of Annual General Meeting
31st Jul 20245:44 pmRNSIssue of Equity
17th Jul 20241:51 pmRNSNet Asset Value(s)
11th Jul 20245:38 pmRNSAnnual Financial Report
24th Apr 20244:49 pmRNSTransaction in Own Shares
5th Apr 20242:54 pmRNSIssue of Equity - 5 April 2024
22nd Feb 20244:38 pmRNSDirectorship Change
15th Feb 202411:53 amRNSIssue of Equity - 15 February 2024
1st Feb 20244:38 pmRNSNet Asset Value - 31 December 2023
10th Jan 20245:27 pmRNSTransaction in Own Shares
21st Dec 202310:08 amRNSDirectorate Change
15th Dec 20233:25 pmRNSIssue of Equity - 15 December 2023
20th Nov 20232:11 pmRNSSeptember 2023 NAV Announcement
13th Nov 20234:46 pmRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.